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Autoimmune diseases such as type 1 diabetes
mellitus, multiple sclerosis (MS), and
rheumatoid arthritis (RA) are immune sys-
tem disorders that share common features of
self-reactive T cells and the presence of auto-
antibodies; as a group they affect some 5% of
the population (Davidson and Diamond
2001). Although their precise etiologies are
unknown, these autoimmune disorders are
generally agreed to reflect interactions of
polygenic traits with various ill-defined
environmental factors (Cantorna 2000;
Dahlquist 1998; Hayes et al. 1997; Karges et
al. 1995; Weinshenker 1996). Descriptive
epidemiology may further elucidate the role
of environmental factors in the etiology of
the autoimmune diseases MS, type 1 dia-
betes, and RA, as well as other immune-
related disturbances such as asthma and
eczema/dermatitis.
MS, type 1 diabetes, and, to a lesser
extent, RA in the Northern Hemisphere,
particularly in Western Europe and North
America, display a latitudinal gradient in dis-
ease frequency, with the prevalence of these
disorders increasing at higher latitudes
(Cantorna 2000; DERIG 1988; Hayes et al.
1997; Karvonen et al. 1993). MS exhibits a
similar prevalence gradient in the Southern
Hemisphere, in Australia and New Zealand
(Hammond et al. 2000; Miller et al. 1990).
In Australia, however, where the opportunity
exists to study gradients in rates across a
large-area population that is less ethnically
and genetically diverse than across Europe,
analyses for other immune-related disorders
have not been done previously.
Ultraviolet radiation (UVR) reaching the
earth’s surface varies inversely with latitude;
UVR is thus a prominent latitude-related
environmental factor. Recent photoimmuno-
logic work shows that UVR downregulates
cellular immunity (Damian et al. 1998; Kelly
et al. 1998), attenuating T-helper (Th)1 T-
cell–mediated immune responses (Clydesdale
et al. 2001). These responses are thought to be
significantly involved in some autoimmune
disorders such as MS, type 1 diabetes, and RA
(Mackay 2000). UVR might therefore be
expected to be beneficial for these disorders.
Few autoimmune or other immune-related
disorders, however, have been assessed ecolog-
ically with respect to UVR. A notable excep-
tion for the Southern Hemisphere is a recent
analysis of MS in Australia, where the regional
variation in MS prevalence was strongly
inversely associated with ambient UVR levels
(r = –0.91; p = 0.01) (van der Mei et al.
2001). This ﬁnding supports the possibility of
UVR being a protective modulator of
immune and autoimmune processes involved
in the etiology of such immune disorders
(McMichael and Hall 1997). Type 1 diabetes
and RA were therefore chosen for ecologic
analysis to determine whether these disorders
showed environmental gradients similar to
those observed for MS in Australia.
By downregulating Th1-mediated immu-
nity, UVR has been thought to effect a shift
from Th1- to Th2-mediated processes
(Clydesdale et al. 2001). Th2 cells are respon-
sible for immediate-type hypersensitivity to
allergens such as dust mites; UVR may thus
have the potential to exacerbate allergic disease
(Selgrade et al. 1997). However, recent work
has cast doubt on the mutual antagonism of
Th1 and Th2 cytokine expression, particularly
in humans (Davidson and Diamond 2001;
Mackay 2000; Platts-Mills 2002; Platts-Mills
et al. 2001). Ultraviolet B, particularly
through interleukin 10, can inhibit both Th1-
and Th2-mediated immune responses in mice
(Garssen et al. 1999). In children, asthma can
coexist with Th1-type disorders such as type 1
diabetes, RA, and celiac disease, suggesting a
common environmental inﬂuence (Kero et al.
2001). A recent randomized controlled trial in
the United Kingdom on adult atopic eczema
has shown UVR, particularly narrow-band
ultraviolet B, to also have a beneficial effect
(Reynolds et al. 2001). Eczema/dermatitis,
together with asthma, were therefore chosen
to be similarly analyzed for regional prevalence
gradients to compare with any associations
evident for type 1 diabetes and RA.
We have examined the association between
latitude and prevalence of the immune-related
disorders type 1 diabetes mellitis, RA,
eczema/dermatitis, and asthma in Australia, a
country with a relatively genetically homoge-
neous population. We further considered
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The apparent immune-suppressive effect of ultraviolet radiation (UVR) has suggested that this
environmental exposure may inﬂuence the development of immune-related disorders. Self-reported
prevalence rates of type 1 diabetes mellitus, rheumatoid arthritis (RA), eczema/dermatitis, and
asthma, from the 1995 Australian National Health Survey, were therefore examined by latitude and
ambient level of UVR. A positive association of type 1 diabetes mellitus prevalence was found with
both increasing southern latitude of residence (r = 0.77; p = 0.026) and decreasing regional annual
ambient UVR (r = –0.80; p = 0.018); a 3-fold increase in prevalence from the northernmost region
to the southernmost region was evident. In contrast, asthma correlated negatively with latitude (r =
–0.72; p = 0.046), although the change in asthma prevalence from the north to the south of
Australia was only 0.7-fold. For both RA and eczema/dermatitis, there were no statistically signiﬁ-
cant associations between latitude/UVR and disease prevalence. These ecologic data provide some
support for a previously proposed beneﬁcial effect of UVR on T-helper 1–mediated autoimmune
disorders such as type 1 diabetes. The inverse association of type 1 diabetes prevalence with UVR is
consistent with that previously reported for another autoimmune disease, multiple sclerosis, in
Australia, and also with type 1 diabetes latitudinal gradients in the Northern Hemisphere. The
ﬁnding also accords with photoimmunologic evidence of UVR-induced immunosuppression and
may suggest a beneﬁcial effect of UVR in reducing the incidence of such autoimmune conditions.
In light of this study, analytic epidemiologic studies investigating risk of immune disorders in rela-
tion to personal UVR exposure in humans are required. Key words: asthma, Australia, autoimmune
disease, ecologic analysis, eczema/dermatitis, immune disorders, latitude, rheumatoid arthritis,
type 1 diabetes, ultraviolet radiation. Environ Health Perspect 111:518–523 (2003).
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ine possible associations between regional and
seasonal UVR levels and the prevalence of
these immune disorders in Australia.
Methods
Prevalence data source. The 1995 Australian
National Health Survey (NHS) was con-
ducted by the Australian Bureau of Statistics
(ABS) during the 12-month period from
January 1995 to January 1996. Approximately
54,000 people from all states and territories
and across all age groups provided information
about their own health status. Residents of a
stratiﬁed, multistage area, random sample of
23,800 private households and households in
nonprivate dwellings were interviewed in per-
son by ABS interviewers; persons within each
state/territory had a known, and in the main
equal, chance of selection. Residents of hospi-
tals and other institutions were excluded,
however, and the Northern Territory (NT)
sample was predominantly urban. Responses
were received from 91.5% of households and
97% of people from these households fully
completed questionnaires. Quarterly popula-
tion estimates were used by ABS for standard-
ization, and prevalence rate estimates were
adjusted for household size (ABS 1995a).
The survey interviewers recorded infor-
mation on recent illness and/or long-term
conditions, as reported by respondents.
Speciﬁc questioning about conditions, includ-
ing diabetes, arthritis, and asthma, was fol-
lowed by action-based questions on recent
visits to hospitals or health professionals.
Information on medication usage, including
insulin and medications for asthma, arthritis,
and allergies, was also elicited (ABS 1995b).
Disease conditions were classified by the
International Classification of Diseases, 9th
Revision (cited by ABS 1995a), categories.
Information recorded in the survey was not
medically veriﬁed, however.
For this study we used summary-data
prevalence estimates for four immune-related
disorders from the published survey results
(ABS 1995c). We compared the age- and
sex-standardized prevalence rates of type 1
diabetes, RA, eczema/dermatitis, and asthma,
per 1,000 population, over the eight major
state and territory regions of Australia, as
listed in Table 1.
Latitude and ultraviolet radiation. The
latitude of the regional capital city (decimal
degrees south; Geoscience Australia mapping
agency) was used for each region (Table 1).
Three UVR measures were examined, each
relating to the Australian UV index (Lemus-
Deschamps et al. 1999) and expressed in milli-
watts per square meter (where 1 UV index
unit = 25 mW/m2). The measures were, for
each regional capital, an arithmetic mean of
12 monthly UV index averages, each monthly
average calculated from single, daily (at local
solar noon), erythemally weighted clear-sky
UV index values derived from ozone data over
the period 1979–1993 (Lemus-Deschamps L.
Personal communication), a midwinter mini-
mum (June) solar-noon UVR value, and a
midsummer maximum (January) solar-noon
UVR value (Table 1).
Statistical analysis. To account for the
NHS sampling variability between regions, we
calculated approximate standard errors (SEs)
for each regional prevalence estimate, as out-
lined in Appendix H and “Technical Note:
Sampling Variability” in the respective ABS
publications (ABS 1995a, 1995c). The
approximate SEs were calculated from SEs for
the corresponding numerator estimates shown
in Table 2, as listed by ABS for each region
(ABS 1995a, 1995c). Age-standardization fac-
tors for the different regions were also applied,
as recommended in the same Technical Note,
and the ﬁnal SEs for the prevalence rates cal-
culated (Table 2). The reciprocal of the vari-
ance of each prevalence rate was then used to
weight the relationships to account for differ-
ing sample sizes in the regions.
Associations between the environmental
variables and the immune disorder prevalence
rates were examined by variance-weighted
least-squares regression of the prevalence rate
estimates versus, first, the latitude values of
the regional capital cities, and second, the
three UVR measures for each of the regional
capitals. The magnitude of change in disease
prevalence rates over the north-south range
was compared by substituting latitude values
for Darwin and Hobart into the regression
equations. The statistical program Stata 7.0
(Stata Corporation, College Station, Texas,
USA) was used for regression analyses.
Table 1. Australian state and territory regions and approximate latitude ranges; regional capitals and their
latitudes (decimal degrees south) shown together with midsummer (January) and midwinter (June) solar-
noon UVRa for each regional capital.
State/territory Latitude range Regional Latitude of Midsummer UVR Midwinter UVR
region for region (degrees) capital capital (degrees) (mW/m2)( mW/m2)
Northern Territory 11–26 Darwin 12.45 339.5 205.9
Queensland 10–29 Brisbane 27.47 332.4 103.9
Western Australia 14–35 Perth 31.95 326.1 82.9
New South Wales 28–37 Sydney 33.87 306.1 66.5
South Australia 26–38 Adelaide 34.93 303.4 60.7
Australian Capital Territory 35–35.5 Canberra 35.30 302.7 55.7
Victoria 34–39 Melbourne 37.82 287.6 48.6
Tasmania 41–43.5 Hobart 42.88 256.7 31.4
aUVR data are monthly averages calculated from daily (at local solar noon) erythemally weighted clear-sky UV Index values
derived from ozone data over the period 1979–1993 (courtesy of L. Lemus-Deschamps, Bureau of Meteorology Research
Center, Australia) and expressed as mW/m2.
Table 2. Regional immune disorder (excluding MS) prevalence ratesa(shaded lines with SEb in parentheses)
together with numerator data on which SE estimates were based.
State/ Type 1 Rheumatoid Eczema/ Regional
territory diabetes arthritis dermatitis Asthma population
Northern Territory
No. cases 200 1,500 2,900 17,200 145,300
Prevalence 2.9 (1.80) 18.2 (5.56) 19.2 (4.43) 127.2 (13.11)
Queensland
No. cases 10,500 82,100 96,900 438,000 3,277,800
Prevalence 3.2 (0.62) 25.7 (1.34) 29.5 (1.40) 132.6 (2.51)
Western Australia
No. cases 6,900 49,000 82,400 201,500 1,732,400
Prevalence 4.2 (0.79) 29.8 (1.66) 47.1 (1.90) 115.2 (2.76)
New South Wales
No. cases 26,300 170,700 181,900 633,700 6,120,500
Prevalence 4.2 (0.56) 27.3 (1.24) 29.8 (1.30) 103.9 (2.10)
South Australia
No. cases 8,300 41,900 73,000 163,500 1,474,800
Prevalence 5.4 (0.63) 26.8 (1.15) 50.3 (1.55) 112.4 (2.16)
Australian Capital Territory
No. cases 1,100 5,600 14,400 35,500 304,900
Prevalence 4.6 (0.99) 21.4 (1.65) 45.5 (3.98) 111.9 (2.65)
Victoria
No. cases 23,800 106,400 171,500 501,500 4,503,100
Prevalence 5.2 (0.50) 23.2 (0.88) 38.2 (1.07) 111.8 (1.63)
Tasmania
No. cases 2,100 19,100 20,700 48,800 473,600
Prevalence 4.5 (1.14) 39.5 (2.38) 44.0 (2.53) 102.1 (3.48)
aRate per 1,000, age- and sex-standardized to the 1995/1996 Australian population. Data from ABS (1995c). bApproximate
SE calculated from ABS-provided SE for numerator (ABS 1995a, 1995c).
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may not have been representative of the
regional population distribution, particularly
for larger regions with the capital at either a
northern or southern extreme of the region
rather than medially placed, a sensitivity analy-
sis was carried out to test the effect of using an
alternative latitude value midway between the
two main population centers in these regions.
Results were then compared with those
obtained from the regional capitals.
Results
Latitude and immune disorders. The
relationships between latitude of the regional
capitals and immune disorder prevalence are
shown in Figure 1 as regression lines ﬁtted to
the prevalence estimates; 95% confidence
intervals (CIs) are also shown, and these indi-
cate, reciprocally, the relative weighting applied
to each estimate in the regression analysis.
Prevalence of type 1 diabetes was positively
correlated with latitude (Pearson r = 0.77; p =
0.026), with the prevalence increasing 2.97-
fold over the north-south latitude gradient.
Asthma prevalence, on the other hand, was
inversely correlated with latitude (Pearson r =
–0.72; p = 0.046), with the prevalence rate
decreasing 0.7-fold, i.e., by approximately one-
third, over the same latitude range. Although
both eczema/dermatitis and, to a much lesser
extent, RA showed trends of increasing preva-
lence with increasing latitude, these were not
statistically signiﬁcant (Figure 1).
Sensitivity analysis. In four of the eight
regions, Western Australia (WA), South
Australia (SA), Victoria (VIC), and Australian
Capital Territory (ACT), at least 70% of the
state or territory populations resided in the
capital metropolitan area (ABS census data
1991/1996, not shown). Among the remain-
ing regions in which the population was more
dispersed outside of the capital, only NT and
Queensland (QLD) were also both of wide
latitudinal range and had capitals located
noncentrally in terms of the regional latitude
range, thus potentially biasing the associations
markedly.
The effect on the initial associations of
using alternative latitude values midway
between the two main population centers,
Darwin and Alice Springs, for NT (i.e., lati-
tude 18.08 degrees south), and Brisbane and
Townsville for QLD (i.e., latitude 23.36
degrees south), was to strengthen the statistical
signiﬁcance of the associations for type 1 dia-
betes, asthma, and eczema/dermatitis when
one or both midway latitudes were substi-
tuted. For example, for type 1 diabetes and
asthma, the statistical signiﬁcance of the asso-
ciations was raised maximally [from p = 0.026
to p = 0.010 for diabetes (r = 0.77 to 0.84),
and from p = 0.046 to p = 0.013 (r = –0.72 to
–0.82) for asthma] when midway latitudes
were used for both regions. Both approaches
unavoidably entail some exposure misclassiﬁ-
cation for dispersed regional populations.
Whereas the latter (midway latitude) approach
may lead to better estimation of the correla-
tion, by using the capital latitude values for
type 1 diabetes and asthma as we have done
(Table 1), the estimate was somewhat biased
toward the null hypothesis of no association
and thus toward underestimation of r.
Similarly, for eczema/dermatitis the statistical
significance was raised maximally [from p =
0.206 to p = 0.174 (r = 0.50 to 0.54)] when
only the QLD latitude was altered, but this
was still nonsignificant at the 5% level. For
RA, on the other hand, using both midway
latitudes gave maximal change, but the statisti-
cal signiﬁcance of the observed trend was low-
ered [from p = 0.727 to p = 0.795 (r = 0.15 to
0.11)]. In summary, the use of the regional-
capital latitude values rather than latitude val-
ues of the midway points did not alter the
overall conclusions of whether the observed
associations were statistically signiﬁcant at the
5% level.
Ultraviolet radiation and immune disor-
ders. In light of the sensitivity analysis, UVR
values for the regional capitals were used. A
solar-noon, clear-sky measure of ambient UVR
was chosen because midday, or noontime,
exposure to the maximal UVR level in sunlight
in Australia suppresses the systemic immune
response in humans (Hersey et al. 1983).
Type 1 diabetes prevalence was inversely corre-
lated with regional average solar-noon UVR
(Pearson r = –0.80; p = 0.018), whereas asthma
prevalence was positively correlated with
regional average solar-noon UVR (Pearson r =
0.73; p = 0.040) (Figure 2). Eczema/dermatitis
and RA prevalence showed inverse trends with
average solar-noon UVR, but these were not
significant (Table 3). The prevalence of
asthma was positively correlated with either
average or midwinter solar-noon UVR but not
midsummer UVR. Although type 1 diabetes
prevalence was inversely correlated with all
three ambient UVR measures, it was more
closely correlated with average or midwinter
solar-noon UVR than with midsummer UVR
(Table 3).
Figure 1. Associations between latitude and prevalence per 1,000 (open circle) of type 1 diabetes, asthma,
eczema/dermatitis, and RA. 95% CIs of prevalence estimates shown as error bars; solid lines denote sta-
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Figure 2. Associations between regional average
ambient solar-noon UVR and prevalence per 1,000
(open circle) of type 1 diabetes and asthma. 95%
CIs of prevalence estimates shown as error bars.
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standardized data on self-reported prevalence
of immune disorders from the ABS 1995
NHS, strong gradients in type 1 diabetes
prevalence with latitude and also, inversely,
with UVR were observed. The magnitude of
change for type 1 diabetes in Australia was an
approximately 3-fold increase in prevalence
from the northernmost region, NT, to the
southernmost region, Tasmania (TAS).
These ecologic data provide support for a
previously proposed beneﬁcial effect of UVR
on autoimmune disorders such as type 1 dia-
betes (McMichael and Hall 1997). In con-
trast to type 1 diabetes, asthma correlated
negatively with latitude and positively with
regional annual or midwinter UVR, but the
magnitude of change for asthma prevalence
from the north to south of Australia was only
0.7-fold. For both RA and eczema/dermati-
tis, there were no statistically signiﬁcant asso-
ciations between latitude/UVR and disease
prevalence.
A strength of this ecologic analysis derives
from the relative genetic homogeneity of the
Australian population (McLeod et al. 1994)
and relative uniformity also in the standard of
national health care. A further advantage is
the wide latitude range and the resulting wide
range of ambient UVR levels over the
Australian continent. A high total response
rate to the survey was achieved by the ABS
over all regions.
One potential source of (probably ran-
dom) error, however, lies in the self-reported,
nonverified nature of the data, which could
have resulted in some misclassiﬁcation of dis-
ease conditions. This is particularly so for
eczema/dermatitis, the classiﬁcation of which
appears to have been based largely on medica-
tion usage; there were no direct disease-speciﬁc
questions on eczema (ABS 1995b). The classi-
fication eczema is often used as an umbrella
term encompassing various dry, itchy skin
conditions (McNally et al. 2000); dermatitis
similarly can include contact dermatitis. Also
the eczema/dermatitis category in the NHS
included heat eczema and sunburn (ABS
1995a), leading to possible regional differences
in prevalence. In addition, although arthritis
was allocated four speciﬁc questions, misclassi-
fication between rheumatoid arthritis,
osteoarthritis, and general arthritic or rheuma-
tism conditions could have occurred. Type 1
diabetes, on the other hand, was classiﬁed on
the basis of 24 direct questions for diabetes
and insulin usage, including duration of use,
both past and future expected use, and age at
ﬁrst use (ABS 1995b). The relative validity of
classiﬁcation of type 1 diabetes, a serious dis-
ease requiring speciﬁc treatment, should there-
fore have been more regionally consistent.
Exposure misclassiﬁcation at the ecologic
(i.e., state or territory) level compared with
the individual level could have occurred
because actual personal UVR exposure
depends on both behavior in relation to the
sun (i.e., whether sun avoidant or taking sun
protection measures) and on regional ambient
UVR. For example, regional UVR would not
have been a good measure of personal sun
exposure among sun-avoidant people, and if
the proportion of such people in each local
population varied markedly, then population-
level exposure assessment would be biased. In
fact, the proportion was small and did not
vary substantially by region [percentage
recording “don’t go out in sun” was 3.4% for
NT, 2.0% for QLD, and 2.3% for TAS (ABS
1995c)]. For most individuals, however, per-
sonal UVR exposure varies between 5 and
15% of daily total ambient UVR (Gies et al.
1999). Ambient UVR levels thus may provide
a reasonable measure of average personal sun
exposure at the population level.
Another possible source of measurement
error—using capital city latitudes and UVR
values as representative of each region—was
shown by sensitivity analysis not to signifi-
cantly bias the results even for the two
regions having the most noncentral capitals
and the widest latitude range, QLD and NT.
However, we considered only current resi-
dence and could not take into account the
contribution of prior residence areas, or the
timing of the critical UVR exposure, which
may have occurred earlier in life, or even
possible migration after disease initiation, as
prevalence rather than incidence data were
used. In addition, we could not control for
latitude when examining the relationships
between the immune disorders and UVR
because of collinearity between UVR and
latitude.
Potential ecologic confounders include
other possible causal factors for immune-
related disorders that vary with latitude or
UVR; for example, regional infection patterns
that may be associated with climatic differ-
ences. Infectious agents have been linked to
the etiology of immune disorders, including
diabetes (Dahlquist 1998; EURODIAB
2000; Kamradt and Mitchison 2001; Notkins
and Lernmark 2001), RA (Albert and Inman
1999; Ebringer and Wilson 2000; Wilson et
al. 2000), and asthma (Blasi et al. 2001). A
lack of infections in early life may also
adversely affect immune development—the
so-called hygiene hypothesis (Bach 2002). A
second important ecologic factor to consider
for asthma is that there are marked regional
differences in allergen levels. For example, an
11-fold higher level of mean house dust mite
allergen (Der p1) concentration in homes in
Sydney, New South Wales (low latitude,
warm and more humid) compared with TAS
(higher latitude, cool and dry) (Couper et al.
1998) may contribute to the inverse latitude
gradient for asthma. Other confounding fac-
tors could include environmental temperature
and dietary differences (Dahlquist 1998).
These potential confounders warrant more
detailed consideration in future research.
There may also be interaction between some
of these environmental exposures, for exam-
ple, infection and nutritional factors
(Haverkos 1997). However, it is not possible
to determine such interactions in ecologic
analyses, as there is a lack of data on joint
environmental exposures at the individual
level (Ponsonby et al. 2002).
UVR has an inverse, or lack of, associa-
tion with the immune-related disorders ana-
lyzed except for asthma, which showed a
positive association between prevalence and
UVR. We are uncertain of the signiﬁcance of
this finding, particularly as the prevalence
increase over the UVR range was only low.
UVR-induced Th2 upregulation is one possi-
bility, but UVR can also suppress Th2
responses (Garssen et al. 1999). In addition,
the contribution of regional allergen levels to
asthma prevalence could be important.
Furthermore, much of asthma at the popula-
tion level may be nonallergic (Pearce et al.
1999), with Th2 mechanisms not involved.
The stronger association found between
latitude and type 1 diabetes prevalence in
Australia is consistent with similar incidence
gradients found in Western Europe and
North America (DERIG 1988; Karges et al.
1995; Karvonen et al. 1993) and also within
China (Yang et al. 1998). The corresponding
inverse association between UVR levels in
Australia and type 1 diabetes prevalence
is also consistent with previous photo-
immunologic work showing that ultraviolet B
irradiation has systemic as well as local
Table 3. Correlations between immune disorder prevalence and regional UVR levels in the 1995 NHS.a,b
Prevalence Regional solar-noon UVR
of disorder Average Midwinter Midsummer
Type 1 diabetes –0.80 (0.018)* –0.77 (0.024)* –0.72 (0.045)*
Eczema/dermatitis –0.47 (0.243) –0.49 (0.215) –0.34 (0.412)
RA –0.08 (0.845) –0.06 (0.880) –0.12 (0.774)
Asthma 0.73 (0.040)* 0.72 (0.044)* 0.68 (0.060)
aPearson correlation coefﬁcients (correlations based on the eight Australian state/territory regions) between immune dis-
order prevalence and solar-noon UVR, for each type of immune disorder and three different measures of UV Index val-
ues—average over year, midwinter minimum, and midsummer maximum. bp-Values in parentheses. Strength of
association examined by variance-weighted least-squares regression. *Statistically signiﬁcant association, p < 0.05.
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animals (Clydesdale et al. 2001; Duthie et al.
1999; Garssen et al. 1999; Sleijffers et al.
2001), as does also ultraviolet A irradiation
(Nghiem et al. 2001). UVR exposure may be
protective against Th1-mediated disorders
such as type 1 diabetes by downregulating
Th1 autoimmune responses by several
different immunoregulatory mechanisms
(Clydesdale et al. 2001; Duthie et al. 1999;
Ponsonby et al. 2002).
One of these possible mechanisms for
downregulation involves UVR-induced vita-
min D. Thus, the proposed protective role of
UVR for autoimmune type 1 diabetes may
act through its important role in vitamin D
synthesis in the skin. Some 90% of plasma
vitamin D in humans is produced endoge-
nously via skin exposure to UVR in sunshine
(Norris 2001) and particularly so in Australia
where foods are not generally fortified with
vitamin D (Mason and Diamond 2001;
Pasco et al. 2001). There are also recent
reports of vitamin D deficiency in some
Australian populations (Grover and Morley
2001), particularly in winter (McGrath et al.
2001; Pasco et al. 2001). For type 1 diabetes,
this possible mechanism is consistent with
recent reports of decreased risk of this disor-
der in offspring of mothers supplemented
with cod liver oil in pregnancy (Stene et al.
2000), and decreased incidence of type 1 dia-
betes in children supplemented with vitamin
D in infancy (EURODIAB 1999; Hypponen
et al. 2001). The Finnish birth cohort study
reported a rate ratio of 0.12 (95% CI,
0.03–0.51) for diagnosis of type 1 diabetes by
adulthood comparing regular versus no vita-
min D supplementation in the first year of
life (Hypponen et al. 2001). These studies
suggest that vitamin D may prevent initiation
of type 1 diabetes, and thus accord with the
vitamin D–protective hypothesis proposed for
this and other autoimmune disorders such as
MS (Cantorna 2000; Hayes et al. 1997). For
MS this hypothesis is consistent with the
recent finding of a strong inverse gradient
between ambient UVR levels and MS preva-
lence in another Australian ecologic study
(van der Mei et al. 2001). Our analogous
ﬁnding for ambient UVR and type 1 diabetes
in Australia supports the specific prediction
that autoimmune diseases other than MS,
such as type 1 diabetes, should show latitude
and/or UVR gradients similar to those seen
for MS if these immune disorders are influ-
enced by UVR exposure (McMichael and
Hall 1997).
In conclusion, our ecologic analysis of
data from the 1995 NHS has demonstrated a
regional gradient of type 1 diabetes prevalence
within Australia that is inversely associated
with regional UVR levels measured at local
solar noon. The inverse association with UVR
is consistent with that found for another
autoimmune disease, MS, in Australia and
consistent with type 1 diabetes latitudinal gra-
dients seen in the Northern Hemisphere. The
ﬁnding is also consistent with photoimmuno-
logic evidence of UVR-induced immuno-
suppression and suggests a beneﬁcial effect of
UVR in preventing both these autoimmune
conditions. Analytic epidemiology studies
investigating risks of type 1 diabetes and other
immune disorders in relation to personal
UVR exposure in humans are now required
(McMichael and Hall 2001).
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